Drugs / RG7652
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01609140 | May 2012 → May 2013 | coronary artery disorder | Genentech, Inc. | Completed | Met primary |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RG7652 | “RG7652 (MPSK3169A), a fully human immunoglobulin G1 (IgG1) monoclonal antibody directed against proprotein convertase subtilisin/kexin type 9 (PCSK9), blocks the interaction...” PMID 28343601 ↗ Mar 2017 |
| Known as | MPSK3169A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01609140 ↗ |
| Action | Inhibit | “blocks the interaction between PCSK9 and low-density lipoprotein (LDL) receptor” PMID 28343601 ↗ Mar 2017 |
| Modality | Monoclonal antibody | “RG7652 (MPSK3169A), a fully human immunoglobulin G1 (IgG1) monoclonal antibody” PMID 28343601 ↗ Mar 2017 |
| Route | Subcutaneous | “given as subcutaneous (SC) injections over a 24-week period” NCT01609140 ↗ |
| Target | PCSK9 | “directed against proprotein convertase subtilisin/kexin type 9 (PCSK9)” PMID 28343601 ↗ Mar 2017 |